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Abstract Cancer cells acquire cell-autonomous capaci-
ties to undergo limitless proliferation and survival through
the activation of oncogenes and inactivation of tumor sup-
pressor genes. Nevertheless, the formation of a clinically
relevant tumor requires support from the surrounding nor-
mal stroma, also referred to as the tumor microenviron-
ment. Carcinoma-associated Wbroblasts, leukocytes, bone
marrow-derived cells, blood and lymphatic vascular endo-
thelial cells present within the tumor microenvironment
contribute to tumor progression. Recent evidence indicates
that the microenvironment provides essential cues to the
maintenance of cancer stem cells/cancer initiating cells and
to promote the seeding of cancer cells at metastatic sites.
Furthermore, inXammatory cells and immunomodulatory
mediators present in the tumor microenvironment polarize
host immune response toward speciWc phenotypes impact-
ing tumor progression. A growing number of studies dem-
onstrate a positive correlation between angiogenesis,
carcinoma-associated Wbroblasts, and inXammatory inWl-
trating cells and poor outcome, thereby emphasizing the
clinical relevance of the tumor microenvironment to
aggressive tumor progression. Thus, the dynamic and recip-
rocal interactions between tumor cells and cells of the
tumor microenvironment orchestrate events critical to
tumor evolution toward metastasis, and many cellular and
molecular elements of the microenvironment are emerging
as attractive targets for therapeutic strategies.
Keywords Tumor microenvironment · InXammation · 
Angiogenesis · Tumor progression · Metastasis
From a cell autonomous to a microenvironmental view 
of cancer
Cancer has been long viewed as a disease consisting of
transformed cells acquiring cell autonomous hyperproli-
ferative, invasive and limitless survival capacities. Accord-
ingly, therapeutic anticancer strategies have been
concentrated on and limited to targeting the tumor cell
itself. Emerging evidence indicates that to eVectively con-
trol cancer, we need to consider carcinogenesis and tumor
progression not as a cell autonomous, cancer cell-centered
condition, but rather as a disease involving complex hetero-
typic multicellular interactions within a newly formed tis-
sue, the cancer tissue. Hence, the concept of tumor
microenvironment as an integrated and essential part of the
cancer tissue was coined (Bissell et al. 2002; Hanahan and
Weinberg 2000). New data emerging from the study of the
tumor microenvironment are forcing the cancer research
community to revise basic concepts of cancer biology. The
tumor microenvironment contains many distinct cell types,
including endothelial cells and their precursors, pericytes,
smooth muscle cells, Wbroblasts, carcinoma-associated
Wbroblasts, myoWbroblasts, neutrophils, eosinophils, baso-
phils, mast cells, T and B lymphocytes, natural killer cells
and antigen presenting cells (APC) such as macrophages
and dendritic cells (Coussens and Werb 2002) (see Fig. 1).
Experimental data have now demonstrated a role for these
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rophages, and cancer-associated Wbroblasts, in promoting
tumor growth and progression. While most cellular compo-
nents of the immune system are capable of rejecting tumors,
in practice they are enslaved by cancer cells to promote their
growth and invasion. Thus, knowledge and control of the
tumor microenvironment is becoming as important as the
knowledge and control of the transformed cancer cells to
better understand cancer biology and to devise novel thera-
peutic approaches (Albini and Sporn 2007).
The Wrst evidence that non-cancerous tissue elements
might aVect tumor formation and growth came from the
Weld of inXammation. A link between inXammation and
cancer has been recognized already in 1863 by Rudolf Vir-
chow, when he reported the presence of leucocytes in tumor
tissues (Balkwill and Mantovani 2001). Based on this
observation he proposed the idea that cancer originates at
sites of chronic inXammation. The presence of leukocytes
in tumors was subsequently interpreted as an aborted
attempt of the immune system to reject the tumor. This
observation remained largely neglected for over a century
until it was demonstrated that innate immune cells, in par-
ticular phagocytes, play an active role in promoting the car-
cinogenesis process. In addition to leukocyte inWltration,
angiogenesis is now being recognized as another stromal
reaction promoting cancer progression. Thus, chronic
inXammatory and neovascularization are critical, if not
essential, for cancer progression (Rüegg 2006).
InXammatory lesions preceding early stages of neoplas-
tic progression contribute to create an environment favor-
able to cancer development. For example, chronic
inXammatory bowel diseases (IBD), such a Crohn’s disease
or ulcerative colitis, or chronic reXux esophagitis in Barrett
syndrome are associated with increased risk of developing
colorectal or esophageal cancer, respectively (van der
Woude et al. 2004). Cancers of infectious etiology have
also been associated with chronic inXammation: for exam-
ple, Hepatitis B and C viruses for hepatic cancer, Schisto-
somes for bladder cancer, and Helicobacter pylori for
gastric cancer (Karin et al. 2006). In many epidemiological
studies the role of chronic inXammation in the carcinogene-
sis process was examined through studies of pro-inXamma-
tory and antiinXammatory cytokines along with other risk
factors including virus-transmitted infections and genetic
markers that take part in the inXammatory response. Exper-
imentally, systemic administration of non-speciWc pro-
inXammatory substances, like LPS, has been shown to
favor tumor growth, angiogenesis and metastatic tumor
spreading to secondary organs (Harmey et al. 2002).
InXammation and tumor progression
Today some of the underlying cellular and molecular
events connecting inXammation to cancer have been uncov-
ered (Mantovani et al. 2008a). Chronic inXammatory
events create a local microenvironment capable of promot-
ing tumor progression though a series of dynamic and
Fig. 1 Heterotypic cellular interactions in the tumor microenviron-
ment. a Tumor cells orchestrate directly (e.g. though the release of fac-
tors) or indirectly (though the induction of tissue hypoxia or
appearance of necrosis) the modiWcation of the microenvironment by
attracting or activating many non-tumoral cells, including blood and
lymphatic endothelial cells and pericytes, carcinoma associated Wbro-
blast, bone marrow-derived cells, immune and inXammatory cells. Tu-
mor cells can also deposit or modify the extracellular matrix. Most of
these stromal modiWcations start early during tumor progression, often
at the transition stage from premalignant to malignant lesions. In some
cases they may even precede cancer formation, for example
in situations of chronic inXammatory conditions. b In turn, tumor
microenvironmental events promote tumor progression by stimulating
tumor growth and survival, and facilitating invasion and metastasis.
Collectively these events will contribute to determine the outcome of
tumor progression: tumor growth, tumor dormancy, tumor invasion
and metastasis and resistance to therapy. Abbreviations: B B lympho-
cyte; BMDC bone marrow-derived cells; BV blood vessel; CAF carci-
noma associated Wbroblast; EC endothelial cell; ECM extracellular
matrix; EMT epithelial to mesenchymal transition; Gr granulocyte;
LEC lymphatic endothelial cell; LV lymphatic vessel; Mo monocyte;
MSC mesenchymal stem cell; PC pericyte; T T lymphocyte; TAM tu-
mor associated monocyte/macrophage; TC tumor cells123
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tory cells (Coussens and Werb 2002). Initially, tumor cells
and cells of the tumor microenvironment, respond to tumor
hypoxia and necrosis secondary to excessive tumor cell
proliferation, by releasing a number of growth factors and
cytokines that are chemoattractive for monocytes and
macrophages, including colony stimulating factor (CSF)-1,
granulocyte–monocyte (GM)-CSF, transforming growth
factor (TGF)-, and chemokines (e.g. CCL2, CCL7, CCL3,
CCL4) (Robinson and Coussens 2005). In turn, recruited
macrophages secrete growth factors that aVect tumor cell
behavior (e.g. induction of motility), activate tumor endo-
thelium and perpetuate inXammation (Allavena et al.
2008b). Factors released by recruited monocytes/macro-
phages include vascular endothelial growth factor (VEGF)-
A and -C, basic Wbroblast growth factor (bFGF), tumor
necrosis factor (TNF), hepatocyte growth factor (HGF),
epidermal growth factor (EGF) family members, platelet-
derived growth factor (PDGF), and chemokines such as
CXCL12 and interleukin (IL)-8 (Benelli et al. 2006; Robin-
son and Coussens 2005). Monocytes and macrophages also
bring in much of the cyclooxygenase-2 (COX-2) present in
the tumor environment. COX-2 expression and prostaglan-
dins production within the tumor environment stimulate
tumor cell proliferation, survival and motility but also
tumor angiogenesis (Prescott and Fitzpatrick 2000).
Because of, COX-2 expression was long though to be
restricted to inXammatory conditions, and potent COX-2
inhibitors (COXIBs) were available to treat inXammatory
conditions, COX-2 appeared suddenly as a ‘magic’ thera-
peutic target for cancer prevention and treatment (Xu
2002). However, the appearance cardiovascular complica-
tions induced by potent COXIBs (Dogne et al. 2006) has
damped enthusiasm and hampered the widespread use of
COXIBs for cancer chemoprevention.
The stroma of a full-blown tumor becomes inWltrated
with many diVerent leukocyte populations, including neu-
trophils, eosinophils, basophils, monocytes/macrophages,
dendritic cells, natural killer cells and lymphocytes (Lin
and Pollard 2004). Tumor inWltrating macrophages, also
referred to as tumor educated or tumor-associated macro-
phages (TAM), are known residents in most neoplastic tis-
sues, where they play a critical role in orchestrating and
promoting tumor growth (Allavena et al. 2008b; Pollard
2004). DeWcient monocyte recruitment at tumor sites in
mice lacking CSF-1 expression was shown to attenuate
late-stage progression and metastasis formation, suggesting
that monocytes contribute to tumor progression (Lin et al.
2001). A positive correlation between the number of TAMs
and poor prognosis has been reported for many cancers.
Importantly, monocytes/macrophages are often present
already at the very early stage of tumor development, in
close associations with areas of hyperplasia and atypia
(Mantovani et al. 2006; Pollard 2004). This observation
further reinforces the notion that macrophages themselves
are driving force contributing to tumor initiation and/or ini-
tial tumor progression. Once recruited to tissue sites, mono-
cytes can assume diVerent phenotypes, epitomized by the
M1 and M2 phenotypes, based on local environmental
stimuli (Allavena et al. 2008a). The M1 phenotype is asso-
ciated with inXammation and microbial killing activity,
whereas the M2 phenotype is associated with tissue remod-
eling and pro-angiogenic activities. The latter are predomi-
nant and crucial events in cancer. Macrophage–tumor cell
interaction leads to the release of macrophage-derived cyto-
kines, chemokines and growth/motility factors (e.g. GM-
CSF, IL-8, EGF) which in turn promote the recruitment of
additional inXammatory cells, thereby amplifying the
inXammatory reaction within the tumor microenvironment
(Balkwill 2004). Chemokines play an important role in
coordinating the stromal response to cancer, including the
polarization of the immune responses to the tumor, the
determination of the composition of the cellular inWltrate,
and the induction of angiogenesis. Chemokine receptors
have been detected on cancer cells and the relevant ligands
were found expressed at the primary tumor site and at sites
of tumor metastasis, suggesting a direct role for chemo-
kines/chemokine receptors in tumor growth and metastasis
(Balkwill 2004).
InXammatory insults lead to upregulation of non-speciWc
pro-inXammatory cytokines such as IL-1/, IL-6, inter-
feron (IFN)- and TNF (Aggarwal et al. 2006; Robinson
and Coussens 2005). Such unresolved chronic inXamma-
tion is associated with increased conversion of normal cells
to preneoplastic foci. Accumulation of somatic mutations
with gain of function can change preneoplastic foci into
foci of fully transformed cells with tumor initiation capaci-
ties. Activated nuclear factor-kappa B (NF-B) transcrip-
tion factor, is one of the main link between inXammation
and tumorigenesis and may be key in allowing both preneo-
plastic and malignant cells to escape apoptosis (Karin 2006;
Naugler and Karin 2008). In addition to macrophages, mast
cells and neutrophils can also support tumor progression by
sustaining inXammation and secreting tumor-promoting
cytokines, growth factors and proteases. For example, in
skin carcinogenesis models, granulocytes were identiWed as
source of MMP-9 expression required for tumor develop-
ment (Coussens et al. 2000). Consistent with this observa-
tion, it has been recently reported that neutrophils also play
a key role in ras oncogene-driven tumor progression (Ji
et al. 2006).
InXammatory cytokines may act as an initiator and pro-
moter of carcinogenesis by directly increasing proliferation
of epithelial cells. InXammation may also promote tumori-
genesis indirectly, by modulating the phenotype and func-
tion of cells mediating speciWc or innate immunity (Rollins123
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genesis, immune suppression and growth promotion, all
characteristic steps of chronic inXammation, to a tumor
suppressive phenotype associated with intense tissue dam-
aging events typical of acute inXammation. Thus, inXam-
matory cells within a tumor mass can be considered as a
double-edged sword (Hagemann et al. 2007): under speciWc
stimulation they can produce antiangiogenic cytokines,
such as IL-12, resulting in suppressed tumor growth. How-
ever, in most tumors inXammatory cells promote tumor
angiogenesis, tumor growth, tumor cell dissemination, tis-
sue breakdown and remodeling. Most tumors are associated
with the activation of tumor-promoting innate immune
responses involving neutrophils, macrophages and NK
cells, while on the other side, speciWc antitumor immune
responses involving B or T lymphocytes are less eYcient in
suppressing tumor growth. Thus, in most cases, cancers
exploit inXammatory and immune inWltrating cells for their
own beneWt.
In spite of the important recruitment of inXammatory
cells in the tumor microenvironment, these cells do not rep-
resent the major cell population of the tumor stroma (Tlsty
and Coussens 2006). Carcinoma-associated Wbroblasts
(CAFs) are the most abundant cells of the tumor microenvi-
ronment (Orimo et al. 2005; Orimo and Weinberg 2006).
CAFs are usually recognized by the expression of -smooth
muscle actin (a-SMA), similar to myoWbroblasts present at
the site of wound healing and chronic inXammation, which
is absent in normal dermal Wbroblasts. CAFs might diVer-
entiate locally from normal stromal Wbroblasts of the sur-
rounding tissue or from bone marrow-derived
mesenchymal stem cells recruited to the tumor. The obser-
vation that CAFs lack genetic mutation or aneuploidy typi-
cally found in the neighboring tumor cells, tend to exclude
a possible tumor origin of these cells following complete
epithelial to mesenchymal transition (EMT) (Kalluri and
Zeisberg 2006).
The immune system and its role in tumor progression
In the early 1900 Paul Ehrlich proposed the notion that the
immune system could be exploited therapeutically to treat
tumors by suggesting the use of antibodies to deliver toxins
to tumor cells (immunotoxis as ‘magic bullets’) (Strom
et al. 1990). Although in practice it has proven diYcult to
create safe and eVective ‘magic bullets’, we have neverthe-
less learned that both innate and adaptive immune
responses can both promote tumor progression or mediate
tumor rejection, as a balance between pro-tumor and antitumor
immunity (Ostrand-Rosenberg 2008). In the tumor micro-
environment the cellular components of the inXammatory
inWltrate and immunomodulatory mediators (cytokines and
chemokines), polarize host immune response toward a spe-
ciWc phenotype, in favoring or suppressing tumor progres-
sion (DeNardo and Coussens 2007; Johansson et al. 2008).
It is nowadays considered that the main mechanism of
tumor immunity is due to an antitumoral T cell response
(Mantovani et al. 2008b). This antitumor response can be
due to the direct killing of tumor cells by CD8 cytotoxic T
lymphocytes (CTL) recognizing major histocompatibility
complex (MHC) class I restricted antigens expressed on the
surface of tumor cells. Oligoclonal tumor-reactive CTLs
can be detected in the blood or among tumor inWltrating
lymphocytes (TILs) in cancer patients. In some cases the
presence of TILs in primary tumors is associated with a bet-
ter prognosis, suggesting that TILs might control tumor
growth (Yu and Fu 2006). However, in most cases the
adaptive immune response against tumor cells is very weak
and largely ineYcient, since the tumor itself and the sur-
rounding microenvironment down-regulate CTL responses
(tumor induced immunosuppression). The fact that CTLs
against human and animal tumors can be easily generated
in vitro using freshly isolated peripheral blood lymphocytes
indicate that the tumor microenvironment has immunosup-
pressive capacities (Mantovani et al. 2008b; Verdegaal
et al. 1999).
Evidence for the existence of a speciWc antibody
response against tumor cells in cancer patients stems from
the observation that sera from some tumor patients speciW-
cally recognize antigens selectively expressed on autolo-
gous tumor cells but not on autologous normal cells.
Recently, using the serological analysis of recombinantly
expressed tumor antigens, a large number of tumor antigens
have been identiWed from the antibody repertoire of cancer
patients. Antitumor antibodies have been detected against
many intracellular antigens, including p53 in patients with
melanoma, hepatocellular carcinoma, colorectal and breast
cancers, and against membrane-associated antigens, such as
Her-2 in patients with breast and prostate cancer (Mittel-
man et al. 2002). Strikingly, the cellular localization of the
recognized antigen has prognostic relevance. Antibodies
detected against intracellular proteins appear to be corre-
lated with poor prognosis, while antibodies reactive against
cell surface components appear to be correlated with a bet-
ter prognosis (Taylor and Gercel-Taylor 1998).
It is generally assumed that growing tumors develop
strategies to evade or limit the eVects of the host’s immune
responses (Drake et al. 2006). These assumptions are based
on the evidence that an eYcient tumor-speciWc immune
response is rarely detectable in patients and that tumor pro-
gression is often associated with the secretion of immuno-
suppressive factors and down-regulation of MHC class I
antigen presentation. Furthermore, as suggested by Gilboa,
increasing immune activity against a tumor in any active or
passive immunotherapy will exacerbate the rate of immune123
Histochem Cell Biol (2008) 130:1091–1103 1095escape and select for a tumor sub-population, which will be
resistant to immunotherapy. Immune escape can be broken
down into several mechanisms, including down-regulation
or loss of tumor-associated antigens (TAA), or the release
of immunosuppressive cytokines (Gilboa 1999). Loss of
TAA expression is one of the main mechanisms by which
tumors escape CTL recognition in vivo. Since intratumoral
TAA expression frequently appears to be heterogeneous,
the emergence of antigen-loss variants due to selection
pressure mediated by a relevant antitumor response
induced by a vaccination strategy is to be expected. The
secretion of immunosuppressive cytokines and chemokines
into the tumor microenvironment, such as TGF-, IL-6 and
IL-10, which can interfere with multiple steps and path-
ways in the generation of an eVective immune response,
has been described in many types of tumors (Mantovani
et al. 2008b). In particular, TGF- is an extremely potent
immunosuppressive factor that aVects proliferation, activa-
tion and diVerentiation of the immune eVector cells and has
been associated with malignant progression (Teicher
2001). The presence of this factor also inhibits the produc-
tion of immunoregulatory cytokines and may also modify
the expression of surface receptors essential for T cell acti-
vation and growth. Concomitantly, TGF- is a potent
inducer of EMT and contributes to promote the invasive
and metastatic behavior of tumor cells (Bierie and Moses
2006b; Lee et al. 2006). IL-6 is expressed in the tumor
microenvironment in 83% of patients with colorectal carci-
noma correlates with unfavorable disease progression
(Piancatelli et al. 1999). IL-6 is also known to have multi-
ple eVects on T cell function, and it may play a signiWcant
role in modulating T cell reactivity at the tumor site.
Recently, has been reported the IL-6/IL-8 interleukin-
dependent inXammatory network contributes to connecting
oncogene-induced cellular senescence, with an inXamma-
tory phenotype and tumor progression (Kuilman et al.
2008). In particular IL-6 acts as a central regulator of this
inXammatory network, also mediates cellular senescence,
reminding a striking parallel with TGF- (Bierie and
Moses 2006a). Both cytokines are able to restrain prolifera-
tion of non-malignant cells present in the tumor microenvi-
ronment, but at the same time they promote proliferation,
invasion and metastasis, thereby reinforcing the close con-
nection between inXammatory mediators and neoplastic
progression.
IL-10 has pleiotropic eVects on T cell functions, includ-
ing the suppression of GM-CSF, IFN- and IL-2 production
by T helper cells, inhibition of T cell proliferation, down-
regulation of expression of adhesion molecules and MHC
class I and class II antigens (Mocellin et al. 2005). Patients
with ovarian carcinoma frequently present abundant levels
of this cytokine in serum, in the peritoneal exudate and in
the tumor tissue. These cytokines inhibit the expression of
immune activating cytokines, such as IL-2 and IL-4
(Benelli et al. 2006; Punnonen et al. 1998). This can inhibit
the natural homeostatic mechanisms that control the spe-
ciWc cellular immunity and could be responsible for the sig-
naling defects in T lymphocytes, routinely observed in late
stage cancer patients, rendering them ineVective in mount-
ing a TAA speciWc eVector activity.
Tumor angiogenesis
Angiogenesis occurs in physiological conditions during
embryonic development, wound healing and tissue regener-
ation (Carmeliet 2005). In these circumstances, angiogene-
sis is a highly regulated process leading to structured,
hierarchically organized and well functioning vascular net-
works. In contrast, in pathological conditions such as can-
cer or chronic inXammation, angiogenesis leads to the
formation of disorganized, chaotic and poorly functioning
vascular networks (McDonald and Choyke 2003). The for-
mation of a tumor-associated (angiogenic) vasculature is a
stromal reaction essential for tumor progression (Carmeliet
and Jain 2000; Kerbel 2008). Tumor-associated vessels
promote tumor growth by providing oxygen and nutrients
and favor tumor metastasis by facilitating tumor cell entry
into the circulation. In the absence of suYcient vasculariza-
tion most tumors cannot exceed a few mm3 in volume, and
remain clinically silent (Folkman 1995). Tumor angiogene-
sis is initiated at discrete time points during tumor progres-
sion (‘angiogenic switch’), which are determined by the
balance between the genetic status of the tumor itself, sig-
nals from stromal and recruited inXammatory cells and by
the appearance of hypoxia (Bergers and Benjamin 2003;
Coussens and Werb 2002). The angiogenic switch often
occurs at the time of the conversion from premalignant to
malignant lesions (Hanahan and Folkman 1996).
Angiogenesis is a multi step process involving diVerent
cell types, in particular endothelial, perivascular cells (i.e.
pericytes, smooth muscle cells), inXammatory and stromal
cells. The cellular and molecular mechanisms of angiogen-
esis have been largely uncovered in recent years (Carmeliet
2000). In order to form new vessels, endothelial cells have
to exit dormancy, proliferate, migrate, diVerentiate, polar-
ize and organize themselves into new tubular structures
within the remodeled stroma. These events are induced and
regulated by diVusible growth and chemotactic factors, cell
adhesion receptors, and instructive molecules. Many
molecular mediators and regulators of angiogenesis are
now known. VEGFs have emerged as critical mediators of
angiogenesis (Ferrara 2005). The principal member of the
VEGF family of factors, VEGF-A binds to and activates
two tyrosine kinase receptors, VEGFR-1 and VEGFR-2. Of
the two, VEGFR-2 is the major mediator of the mitogenic,123
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The signiWcance of VEGFR-1 in the regulation of angio-
gensis is more complex (Shibuya 2001). Under some cir-
cumstances, the higher aYnity VEGFR-1 may function as a
‘decoy’ receptor that sequesters VEGF and prevents its
interaction with VEGFR-2. Alternatively, VEGFR-1 may
regulate function of VEGFR-2 (cross talk). There is grow-
ing evidence that VEGFR-1 has signiWcant roles in haemato-
poiesis and in the recruitment of monocytes and other
bone-marrow-derived cells that may home in on the tumor
vasculature and promote angiogenesis. VEGFR-1 is
involved in the induction of matrix metalloproteinases
(MMPs) and in the release of matrix-bound growth factors.
Furthermore, in some cases VEGFR-1 is expressed by
tumor cells and may mediate a chemotactic signal, thus
potentially extending the role of this receptor in cancer
growth (Gerber and Ferrara 2003).
VEGF is strongly induced by hypoxia forming within
the tumor microenvironment. The transcription factor
hypoxia inducible factor (HIF) 1 plays a central role in the
hypoxic regulation of VEGF (Semenza 2002). HIF1 is
constitutively produced in excess but rapidly degraded
under normoxic conditions. The von Hippel–Lindau (VHL)
tumor suppressor protein targets it for ubiquitination and
subsequent proteasomal degradation (Semenza 2001). In
situ hybridization studies demonstrate that VEGF mRNA is
expressed in many tumors. Renal cell carcinomas have a
particularly high level of VEGF expression, consistent with
the notion that inactivating VHL mutations occur in about
50% of such tumors, thus providing a further explanation
for the responsiveness of this tumor type to a VEGF block-
ade (Haase 2006). Strikingly, HIFs have been shown to
activate speciWc signaling pathways such as Notch and
Oct4 that control stem cell self renewal and multipotency,
suggesting a possible link between hypoxia and stemness
(Keith and Simon 2007). Hypoxia, however, is not the only
mechanism regulating VEGF expression in tumors. A
broad and diverse spectrum of oncogenes can induce VEGF
expression, including mutant ras, erbB-2/Her2, activated
EGF receptor and bcr-abl. Besides VEGF, other vascular
growth factors, including b-FGF, IL-8, TGF-, TNF and
molecules promoting, mediating or regulating angiogene-
sis, have been identiWed and characterized in recent years.
They include adhesion molecules of the integrin and cad-
herin families, such as V3, 51, and VE-cadherin;
extracellular matrix proteins, such as Wbronectin, collagens,
and laminins; remodeling and morphogenic molecules and
their receptors, in particular Angiopoietins/Ties, Notch and
Delta-like ligands, Eph and Ephrins, semaphorins, neuro-
pilins and the plexins; proteinases such as MMP-2 and -9,
plasminogen activators (u-PA and t-PA) and their inhibitors
(TIMPs and PAIs); intracellular signaling molecules, most
notably protein kinases (e.g. raf and mitogen activated
protein kinase (MAPK), protein kinase A (PKA), protein
kinase B (PKB/Akt) and GTPases (e.g. Ras and Rho
families), and many transcription factors and transcriptional
regulators (besides HIF-1), such as inhibitors of diVerenti-
ation (Id1/3), NF-B and homeobox gene products (e.g.
Hox D3 and B3). (For review on mechanisms see the
following publications and references herein: Avraamides
et al. 2008; Bergers and Benjamin 2003; Jain 2003;
Karamysheva 2008; Kerbel 2008; Neufeld and Kessler
2008; Pugh and RatcliVe 2003; Rüegg and Mariotti 2003;
Semenza 2007).
The recent discovery that VEGFR-3 and its ligands
VEGF-C and -D promote lymphatic vessel formation (lym-
phangiogenesis) has boosted research on tumor lymph-
angiogenesis (Alitalo and Carmeliet 2002). Expression of
VEGF-C or -D by tumor cells induces lymphatic vessel for-
mation around the tumors and promotes metastatic tumor
spreading at draining lymph nodes and distant organs.
While it is clear that lymphatic vessels facilitate metastatic
tumor spreading, the exact mechanism by which this occurs
has not been fully elucidated (Alitalo et al. 2005).
InXammatory cells promote tumor angiogenesis
It is becoming increasingly evident that inXammatory cells
recruited in the tumor stroma play a pivotal role in trigger-
ing tumor angiogenesis (Rüegg 2006; Shojaei et al. 2008).
It has been proposed that inXammatory cells might in fact
be responsible for a substantial portion of tumor angiogene-
sis by acting as initiator of vascularization. Thus antiinXam-
matory drugs might be suitable tools in anticancer therapy.
Innate immune (i.e. macrophages, neutrophils) release a
number of factors able to stimulate and activate endothelial
cells, such as VEGF, HGF, MMP-2, MMP-9 and IL-8.
Neutrophils were largely ignored for a long time in the con-
text of tumor angiogenesis but recent studies have shown
their important role in this process (Coussens and Werb
2002). Furthermore, the Human ImmunodeWciency Virus
(HIV) viral transactivator protein Tat activates neutrophils
as part of its angiogenic activity and angiostatin exerts its
antiangiogenic activity, at least in part, through its interac-
tion with neutrophils (Benelli et al. 2003). The close rela-
tionship between inXammation and angiogenesis observed
within tumors is likely due to the natural physiological rela-
tionship between these two compartments. Endothelial cells
and cells of the immune/inXammatory system are derived
from a common hematopoietic precursor cell (Dzierzak and
Speck 2008). Endothelial and immune cell are used to
interact with each other, for example during leukocyte and
lymphocyte traYcking across the endothelium and immune
cells can aVect vascular functions. Many angiogenic factors
inXuence the activity of immune cells that generally favor123
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sical tumor-endothelium axis widely studied in the angio-
genesis Weld, it emerges that inWltrating inXammatory cells
favor the cross-talks between tumor cells and endothelial
cells, thereby creating a tumor-inXammation-endothelium
axis, which may open new therapeutic perspectives (Noo-
nan et al. 2008; Shojaei et al. 2008). In addition, to classical
inXammatory cells, bone marrow-derived cells (BMDC)
has been recently shown to be mobilized from the bone
marrow in response to stimuli originating form the growing
tumor, and to recruit at tumor sites to promote tumor angio-
genesis and tumor invasion. Furthermore, tumor-mobilized
myeloid cells can also be directed to diVerent organs where
they can form premetasitatic niches, which favor homing
and survival of circulating tumor cells thereby promoting
metastasis formation (Kaplan et al. 2006a).
Antiangiogenic therapy is in clinical practice
In experimental models, inhibition of the angiogenic switch
prevents progression of hyperplastic foci to in situ carci-
noma, decreases cancer insurgence and reduces metastasis.
Targeting tumor angiogenesis to inhibit tumor growth has
now become a clinical reality. In pathological conditions,
such as cancer, endothelial cells are constantly stimulated
by angiogenic factors and fail to form a diVerentiated,
mature and stable vascular network (Kerbel 2008). Imping-
ing on factors stimulating endothelial cells, results in the
inhibition or even regression of angiogenic vessels (Ferrara
and Kerbel 2005). Conceptually, it has been proposed that
therapeutic targeting of non-tumoral cells would circum-
vent the problem of drug resistance and selection of escape
variants, since these cells are genetically stable (in contrast
to tumor cells). Furthermore, one given antiangiogenic
therapy would suit diVerent tumor types. Preclinical experi-
ments and clinical studies demonstrated that reality is far
more complex. In fact, the vast majority of drugs that were
active in preclinical models failed to show eYcacy in clini-
cal trials (Kerbel and Folkman 2002). In spite of some ini-
tial negative clinical trials, major progress has been made
over the past few years in targeting angiogenesis for human
therapy, and inhibition of angiogenesis is now established
as a new therapeutic approach to control tumor progression
(Kerbel 2008). To date four antiangiogenic drugs are in
clinical use after approval by the Food and Drug Adminis-
tration (FDA): Avastin (bevacizumab) (Ferrara et al. 2005),
a humanized anti-VEGF monoclonal antibody, for the treat-
ment of metastatic colorectal cancer, in combination with
chemotherapy, Nexavar (sorafenib) (Rini 2006), Sutent
(sunitinib) (Motzer et al. 2006), two multi-tyrosine kinase
inhibitors, and Torisel (temsirolimus) (Dancey 2005), an
inhibitor of the mammalian target of rapamycin (mTOR)
kinase. These drugs showed to extend survival of patients
with advanced cancers (Sessa et al. 2008). Importantly,
these compounds all target the VEGF pathway, either by
inhibiting VEGF, its receptors or downstream molecules.
Thus, to date the VEGF pathway is the best-characterized
and validated therapeutic target to inhibit tumor angiogene-
sis for renal and gastrointestinal stromal tumors (GIST)
(with Sorafenib and Sunitinib) without need for concomi-
tant chemotherapy. In contrast, in lung, colorectal and
breast cancers, survival beneWt is only observed when anti-
angiogenic drugs are administered in combination with
chemotherapy (Jain et al. 2006; Sessa et al. 2008)
Taken together, these achievements validated the con-
cept that angiogenesis is a relevant therapeutic target in
cancer. So far antiangiogenic drugs are being administered
to patients with advanced cancers, and the impact on cancer
progression and overall survival has remained small. It will
be important to test whether antiangiogenic therapy admin-
istered in adjuvant settings may have a more signiWcant
impact on the survival of patients at risk for relapse. Fur-
thermore, recent experimental evidence indicates that
tumors can develop resistance to antiangiogenic therapy
(Bergers and Hanahan 2008). This has been shown by
inhibiting VEGF pathway and demonstrating that tumors
resume angiogenesis by using alternative angiogenic fac-
tors, such as FGF-2 (Casanovas et al. 2005). It will be
important to identify escape mechanisms of angiogenesis
that could be targeted to improve eYcacy of current antian-
giogenic treatments.
The tumor microenvironment as a niche favoring tumor 
cell survival and metastasis
Normal cells survive and grow within deWned environmen-
tal niches and are subjected to microenvironmental control.
Outside of their speciWc niche, the tissue environment is
hostile to normal cells. Since they lack necessary cell
autonomous survival signals, normal cells will not survive
an inappropriate microenvironment (Morrison and Spra-
dling 2008). Detachment-induced cell death (anoikis) has
been proposed as the mechanism preventing normal cells
from leaving their original environment and seeding at
inappropriate locations (Chiarugi and Giannoni 2008). In
order to evade local tissue control and avoid anoikis during
tumor development and progression, malignant cells start
interacting with the surrounding extracellular matrix
(ECM) (Reddig and Juliano 2005). A bidirectional relation-
ship is initiated between tumor cells and its surrounding
stroma as a Wrst step to invasive growth on metastatic
spreading (Bidard et al. 2008; Kopfstein and Christofori
2006; Weinberg 2008). Stromal changes sustaining tumor
progression include modiWcations of the extracellular123
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cells, and the recruitment of pericytes or smooth muscle
cells and immune and inXammatory cells (Tlsty and Cous-
sens 2006).
In recent years, evidence accumulated suggesting that a
small tumor cell subpopulation in the primary tumor mass
might be responsible for tumor initiation, growth, mainte-
nance and spreading. These cells, termed cancer stem cells
or cancer initiating cells (CSC/CIC), represent a population
with stem cell-like properties, in particular long-term sur-
vival, high self-renewal and seeding capacities (Barnhart
and Simon 2007; Croker and Allan 2008; Hambardzumyan
et al. 2008; Visvader and Lindeman 2008). While the cellu-
lar origin of CSC/CIC and the associated molecular path-
ways are still matter of discussion, the existence of a small
tumor cell subpopulation capable of initiating and main-
taining tumor growth and initiating metastasis is being
increasingly documented and accepted (Rossi et al. 2008;
Tan et al. 2006). Furthermore, evidence indicates that CSC/
CIC are more resistant to classical therapeutic approaches
(i.e. chemotherapy and radiotherapy) compared to the bulk
of the tumor cell mass. The mechanism of resistance
remains largely elusive and might include the increased
expression of multi-drug resistance-type of membrane
transporters or a protective eVect of the microenvironment.
Initial evidence for the existence of CSC/CIC came from
the hematopoietic system, where in acute myeloid leukemia
rare leukemic (stem) cells with a CD34+/CD38¡ phenotype
were shown to eYciently initiate transplantable experimen-
tal tumors in mice (Blair and Pamphilon 2003). Subse-
quently, it has been demonstrated that tumor cell
subpopulations with similar features, but diVerent surface
phenotypes, also exist in solid tumors (Ailles and Weiss-
man 2007; Cho and Clarke 2008). In all cases, CSC/CIC
are distinguished from the somatic” tumor cell population,
by their capacity to eYciently generate new tumors when
implanted at low number in mice. Conversely, “somatic”
cancer cells are not able to initiate tumor growth, even in
high number, in the same in vivo preclinical models.
While the crucial role of the tumor microenvironment in
controlling tumor progression and metastasis is now widely
accepted, the formation of a specialized environment sup-
porting CSC/CIC survival and growth (the CSC niche), its
anatomical organization and the cellular and molecular
mediators of these eVects, are still under investigation
(Sneddon and Werb 2007). The recent identiWcation of
human normal brain cells with self-renewal potential
(reported as neural stem cells) that populate the subventric-
ular zone, has contributed to the characterization of their
niche and to the subsequent identiWcation and characteriza-
tion of brain tumor CSC/CIC and their niche. Brain tumor
CSC/CIC are localized in a vascular niche that is supposed
to provide factors promoting their self-renewal (Calabrese
et al. 2007; Veeravagu et al. 2008). Perturbation of this
niche results in a compromised ability CSC/CIC to promote
tumor growth within the brain (Gilbertson and Gutmann
2007; Gilbertson and Rich 2007). These observations dem-
onstrate the relevance of the vascular niche to tumor patho-
physiology, and suggest the possibility to target the niche
itself, and associated molecular events, to impinge on can-
cer stem cells for therapeutic purposes (Croker and Allan
2008).
A still open issue in the Weld is the deWnition of CSC/
CIC through phenotypical markers allowing their accurate
identiWcation and isolation from the bulk of the tumor cell
population in human and experimental tumors (Cho and
Clarke 2008; Visvader and Lindeman 2008). Some markers
have been proposed, including CD44+/CD24¡ in breast
cancer, or CD133+ in brain, colon and pancreatic tumors.
CD133, however, is also expressed by many normal stem
cells in hematopoietic, neural and epithelial tissues (Wood-
ward and Sulman 2008). Isolation of CSC/CIC from spe-
ciWc tumor types would allow their comparison with
“somatic” cancer cells and open the way to the identiWca-
tion or speciWc gene expression proWles responsible for the
aggressive CSC/CIC phenotype, including resistance to
therapy (Cho and Clarke 2008; Dean et al. 2005).
The premetastatic niche: A niche for CSC/CIC ?
To explain how cancer cells can migrate from a primary
site to colonize speciWc distant sites to grow and form
metastases, Stephen Paget proposed the “seed and soil”
hypothesis more than a century ago (Ribatti et al. 2006).
This theory was based on the observation that tumors do
not metastasize randomly but rater at preferred sites. Paget
proposed that the formation of metastasis depends both on
the properties of the tumor cells (seed) as well as the per-
missive role of the environment (soil) at the distant site.
This hypothesis by which cancer cells are able to survive
and proliferate only at speciWc secondary sites where there
is an ideal environment that releases molecular mediators
suitable for that type of cancer cells, still represents a main
conceptual model of metastasis in modern cancer research
(Steeg 2007; Talmadge 2007).
Metastasis formation itself is a multi-step process that
require tumor cells to escape from the primary site, intrava-
sate into the hematic or lymphatic circulation, migrate and
extravasate into secondary organs (Christofori 2006; Steeg
2006). Recent work has shed new light on the genetic,
molecular and cellular basis of metastasis (Gupta and Mas-
sague 2006; Nguyen and Massague 2007). CSC/CIC might
represent the unique sub-population of cells with the poten-
tial to successfully form metastasis in a distant organ (Li
et al. 2007; Wicha 2006). Metastasis formation, however, is123
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cancer cells to Wnd a proper microenvironment for initiating
tumor growth in a secondary organ. It has been proposed
that in order to form metastases, primary tumors might pro-
duce factors that induce the formation of a suitable and
appropriate environment in the organ where metastasis will
be seeded. This has lead to the concept of the premetastatic
niche, whereby a special, permissive microenvironment in
secondary target organs is induced over distance by the pri-
mary tumor (Kaplan et al. 2006b). In this sense, there is a
striking parallel between CSC/CIC maintenance and expan-
sion in the primary tumor and formation of metastases in a
distant organ. Both events require a particular niche or
microenvironment and might share many cues promoting
self-renewal ability, migration and invasion, resistance to
apoptosis, and increased resistance to cytotoxic drugs. The
Wrst in vivo experimental evidence that metastatic seeding
requires the formation of a niche was the discovery that
VEGFR-1+ BMDC colonize target organs to form tumor-
speciWc premetastatic sites, before the arrival of the meta-
static tumor cells themselves (Kaplan et al. 2005). In these
sites BMDC express several hematopoietic markers, such
as CD34, CD116, c-kit, Sca-1, as well as integrins (e.g.
41), chemokines and chemokine receptors (e.g.
CXCL12/CXCR4), promoting either their homing to the
target tissue or recruitment and attachment of tumor meta-
static cells, or both.
Among the chemokines involved in tumor metastasis,
the CXCL12 (also known as SDF-1 or stromal-derived fac-
tor)/CXCR4 axis plays a critical role in stem cell migration
(Petit et al. 2007). Activation of CXCR4 induces motility,
chemotactic response, adhesion, secretion of MMPs and
release of angiogenic factors, such as VEGF-A. Interest-
ingly this premetastatic niche, like the normal niche, is
characterized by the presence of speciWc ECM proteins,
such as Wbronectin, a ligand for 41 expressed on
VEGFR-1+ cells. Thus, it appears that in order to survive at
distant sites, disseminating tumor cells need to recreate a
supportive microenvironment similar to the one formed in
the primary tumor. One eYcient way to do it is by directing
BMDC or immune/inXammatory cells to these distant sites
of future metastasis (DeNardo et al. 2008). The chemoat-
tractant proteins S100A8 and S100A9 were the Wrst factors
shown to instruct the formation of the premetastatic niche
(Hiratsuka et al. 2008; Kaplan et al. 2006b). Additional
studies are needed to further elucidate the biological mech-
anisms involved in the formation of this premetastatic
niche, in particular regarding the identiWcation of the
molecular mechanism responsible for the development of
clinically relevant metastases from the initial seeds. The
unraveling of such mechanisms could be useful for the
development of a more accurate knowledge about the meta-
static process, with major clinical implications to the
prevention, monitoring and management of metastatic
tumor spreading (Steeg and Theodorescu 2008).
Therapy-induced modiWcation of the tumor 
environment impacts tumor progression
It is generally assumed that tumor escape and progression
toward metastasis during or after therapy is due to the
appearance of resistant tumor cells through a combination
of therapy-induced genetic instability and subsequent
clonal selection of the most Wtted cell. This assumption
appears particularly relevant to radiotherapy, since the
antitumor eVect of radiotherapy on tumor cells involve
double strand DNA breaks (Gudkov and Komarova 2003).
Most cells with damaged DNA undergo p53-mediated
apoptosis, mitotic cell death or senescence-like irreversible
growth arrest. However, surviving cells might have
increased genomic instability and mutations due to mis-
matched DNA repair and have the potential to rapidly
evolve toward a more aggressive phenotype. Recent Wnd-
ings indicate that radiotherapy also rapidly and persistently
alters the tissue microenvironment. These modiWcations
aVect cell phenotype, tissue metabolism, bidirectional
interactions and signaling events between cells (Barcellos-
HoV et al. 2005). While there is evidence indicating that
these changes might contribute to the antitumor eVects of
radiotherapy, for example by creating a Wbrotic scar tissue
restraining tumor invasion, there are also clinical and
experimental observations indicating that irradiated stroma
might exert tumor-promoting eVects (Barcellos-HoV et al.
2005). Experimentally, tumors growing within a preirradi-
ated stroma have reduced growth but show more invasive
and metastatic phenotype, an eVect known as the tumor
bed eVect (Milas et al. 1987, 1988). Clinically, while adju-
vant radiotherapy signiWcantly improves local tumor con-
trol (Bartelink et al. 2001), tumor recurrences within a
preirradiated Weld are associated with higher risk of local
invasion and metastasis and poor prognosis compared to
recurrences outside the irradiated area (O’Brien et al.
1986; Suit 1992; Vicini et al. 2003; Vikram et al. 1984).
We have recently reported that tumors growing in a preir-
radiated bed have reduced angiogenesis and are more hyp-
oxic compared to control tumors (Monnier et al. 2008).
Tumor cells derived from these hypoxic tumors retain an
invasive behavior in vitro and metastatic capacities in
vivo, even after prolonged in vitro culture. A similar phe-
notype was observed when tumor cells were selected
through repeated cycles of hypoxia in vitro, demonstrating
that hypoxia was suYcient for the selection of resistant
cells. Through gene expression proWling and gain and loss
of function experiments, we identiWed the matricellular
protein CYR61 and the integrin adhesion receptor V5,123
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oxic condition, invasion and metastasis. Importantly, phar-
macological inhibition of V5 with a small molecular V
integrin inhibitor EMD121974 (cilengitide) (Smith 2003)
and an anti-V antibody, suppressed invasion and metasta-
sis induced by CYR61 and attenuated metastasis of tumors
growing within a preirradiated Weld in a cell autonomous
manner. Based on these Wndings, we propose a model in
which irradiation impairs the ability of the tumor stroma to
elicit an eVective angiogenic response, and that tumors
growing within this angiogenesis-deWcient stroma develop
sustained hypoxia, which in turn, acts as a strong factor to
select for hypoxia resistant, invasive and metastatic cells.
Irradiated stroma itself might also actively contribute to
create a microenvironment favoring tumor cell survival,
invasion and metastasis. The radiation therapy response of
the tumor microenvironment comprises an increased secre-
tion or activation of many antiapoptotic (e.g. insulin-like
growth factor-1) and pro-inXammatory cytokines (e.g.
GM-CSF), or tumor promoting factors, such as EGF, G-
CSF, FGF or TGF-. Some of the tumor-promoting eVects
of irradiated stroma may be indirect though the recruit-
ment of BMDC from peripheral blood, further boosting
and sustaining the microenvironment itself.
Furthermore, there are emerging data on CSC/CIC and
resistance to radiation therapy: this radioresistant sub-popu-
lation within the tumor mass shows a 50% lower dose-
dependent formation of reactive oxygen species in response
to radiation and reduced or even absent double-strand DNA
breaks. In a breast cancer experimental model, CSC/CIC
(as deWned by the CD44+/CD24¡ phenotype) derived from
MCF-7 and MDA-MB-231 human cancer lines were iso-
lated and exposed to a single dose of radiation. These cells
were more resistant to radiation therapy, had few or no dou-
ble-strand DNA breaks, and a 50% decrease in dose-depen-
dent formation of reactive oxygen species, compared to the
bulk of cancer cell population (Phillips et al. 2006). In
another study, CD133+ CSC/CIC isolated from glioma
showed increased survival after radiation treatment as com-
pared to the CD133¡ cells, preserving the tumor-forming
ability and aggressive phenotype of the non-irradiated
CD133+ cells (Chiou et al. 2008). CSC/CIC appear to sur-
vive better and to repair DNA more eYciently compared to
the bulk of the tumor cell population, and this in turn could
make the tumor more resistant to radiotherapy. Thus, radio-
therapy might modify the microenvironment in a way to
favor the survival of CSC/CIC, thereby explaining the
increased aggressive behavior of tumors recurring within a
preirradiated bed. The contribution of tumor microenviron-
ment to promote survival of CSC/CIC could represent a
novel therapeutic target to prevent or manage cancer recur-
rences after radiotherapy.
Conclusions
In recent years the study of tumor microenvironment, its
cellular and molecular components, and how they can aVect
neoplastic progression, has become an emerging topic in
cancer research. Factors released by the tumor cells them-
selves, in particular pro-/antiinXammatory molecules or
pro-/antiangiogenic mediators, and factors polarizing
immune surveillance toward a tumor-permissive or tumor-
rejecting phenotype contribute in creating an environment
mostly friendly and sometimes hostile to the tumor. Impor-
tantly, events and molecules implicated in this cross talk
within the tumor microenvironment have emerged as
attractive targets in anticancer therapeutic intervention.
The introduction in the clinic of antiangiogenic drugs
has been widely recognized as a major breakthrough in bio-
medical research and clinical oncology. This represents a
proof-of-concept indicating that targeting stromal events
can impact tumor progression. More recent works suggest
that stromal events may also modulate the response of can-
cer cells to therapeutic interventions targeting the tumor
cells themselves, in particular chemotherapy, and may con-
tribute to the emergence of resistance to therapy. While
several mechanisms of resistance to antiangiogenic treat-
ments have been proposed, there is a limited knowledge on
how tumor cells and the microenvironment respond, adapt
and evolve under this therapeutic approach.
Taken together, these Wndings emphasize the need to
further unravel the complex molecular networks and cross
talk between diVerent components of the tumor microenvi-
ronment and the tumor cells itself. A deepened knowledge
on mechanisms involved in tumor progression and inva-
siveness toward metastasis could be essential to improve
eYcacy of current therapeutic interventions with signiWcant
clinical impact.
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